France
Mablink Bioscience
Mablink aims to transform the immunotherapy of cancers with its next generation Antibody-Drug Conjugates (ADC), leveraging PSARlink', its innovative proprietary hydrophilic drug-linker platform. Mablink is developing its own pipeline of ADCs.
CREATION
EMPLOYEES
CITY
LYON
DEVELOPMENT LEVEL
FUNDRAISING
FUNDRAISING AMOUNT
35000000
